CN104666327B - The application of oligomannuronic acid and its derivative in the medicine and health products for preparing antifatigue and anti-amyotrophia - Google Patents
The application of oligomannuronic acid and its derivative in the medicine and health products for preparing antifatigue and anti-amyotrophia Download PDFInfo
- Publication number
- CN104666327B CN104666327B CN201510018297.9A CN201510018297A CN104666327B CN 104666327 B CN104666327 B CN 104666327B CN 201510018297 A CN201510018297 A CN 201510018297A CN 104666327 B CN104666327 B CN 104666327B
- Authority
- CN
- China
- Prior art keywords
- amyotrophia
- medicine
- oligomannuronic acid
- application
- oligomannuronic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002253 acid Substances 0.000 title claims abstract description 65
- 201000000585 muscular atrophy Diseases 0.000 title claims abstract description 41
- 239000003814 drug Substances 0.000 title claims abstract description 30
- 230000002929 anti-fatigue Effects 0.000 title claims abstract description 27
- 230000036541 health Effects 0.000 title claims abstract description 20
- -1 mannuronic acid compound Chemical class 0.000 claims abstract description 5
- 229920002527 Glycogen Polymers 0.000 claims description 21
- 229940096919 glycogen Drugs 0.000 claims description 21
- 210000003205 muscle Anatomy 0.000 claims description 21
- 210000004369 blood Anatomy 0.000 claims description 20
- 239000008280 blood Substances 0.000 claims description 20
- 210000002966 serum Anatomy 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 210000002027 skeletal muscle Anatomy 0.000 claims description 11
- 102100026189 Beta-galactosidase Human genes 0.000 claims description 10
- 108010059881 Lactase Proteins 0.000 claims description 10
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 10
- 229940116108 lactase Drugs 0.000 claims description 10
- 230000002440 hepatic effect Effects 0.000 claims description 9
- 230000033001 locomotion Effects 0.000 claims description 9
- 238000009825 accumulation Methods 0.000 claims description 7
- 239000003862 glucocorticoid Substances 0.000 claims description 7
- 241000512259 Ascophyllum nodosum Species 0.000 claims description 6
- 235000010443 alginic acid Nutrition 0.000 claims description 6
- 229920000615 alginic acid Polymers 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 230000011987 methylation Effects 0.000 claims description 6
- 238000007069 methylation reaction Methods 0.000 claims description 6
- 229920001542 oligosaccharide Polymers 0.000 claims description 6
- 230000026731 phosphorylation Effects 0.000 claims description 6
- 238000006366 phosphorylation reaction Methods 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 4
- 150000002482 oligosaccharides Chemical class 0.000 claims description 4
- 241000195493 Cryptophyta Species 0.000 claims description 3
- 241000227647 Fucus vesiculosus Species 0.000 claims description 3
- 241000737023 Zebrasoma flavescens Species 0.000 claims description 3
- GZCGUPFRVQAUEE-KVTDHHQDSA-N aldehydo-D-mannose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O GZCGUPFRVQAUEE-KVTDHHQDSA-N 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 229910052744 lithium Inorganic materials 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 240000002900 Arthrospira platensis Species 0.000 claims description 2
- 235000016425 Arthrospira platensis Nutrition 0.000 claims description 2
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 240000001307 Myosotis scorpioides Species 0.000 claims description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 2
- 241001165494 Rhodiola Species 0.000 claims description 2
- 235000013793 astaxanthin Nutrition 0.000 claims description 2
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 2
- 229940022405 astaxanthin Drugs 0.000 claims description 2
- 239000001168 astaxanthin Substances 0.000 claims description 2
- 238000013329 compounding Methods 0.000 claims description 2
- 235000008434 ginseng Nutrition 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 229940109850 royal jelly Drugs 0.000 claims description 2
- 229940082787 spirulina Drugs 0.000 claims description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims 1
- 241000208340 Araliaceae Species 0.000 claims 1
- 229930182470 glycoside Natural products 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 abstract description 12
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 10
- 238000002474 experimental method Methods 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 5
- 238000012360 testing method Methods 0.000 abstract description 4
- 206010028289 Muscle atrophy Diseases 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract description 2
- 210000000107 myocyte Anatomy 0.000 abstract description 2
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 229930014626 natural product Natural products 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 230000009182 swimming Effects 0.000 description 27
- 206010016256 fatigue Diseases 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 description 10
- 102000007469 Actins Human genes 0.000 description 9
- 108010085238 Actins Proteins 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000008859 change Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 235000019624 protein content Nutrition 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229960002666 1-octacosanol Drugs 0.000 description 3
- 241000581650 Ivesia Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 210000002363 skeletal muscle cell Anatomy 0.000 description 3
- 230000034512 ubiquitination Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000006652 catabolic pathway Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000003098 myoblast Anatomy 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- AEMOLEFTQBMNLQ-SYJWYVCOSA-N (2s,3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-SYJWYVCOSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002027 Amyotrophy Diseases 0.000 description 1
- 102000040350 B family Human genes 0.000 description 1
- 108091072128 B family Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- WJXICLCJFVEKKK-PWVLCOLPSA-N NC1=NC=NC2=C1N=CN2[C@@H]([C@@H]1O)O[C@H](COP(O)(O)=O)[C@H]1O.NC1=NC=NC2=C1N=CN2[C@@H]([C@@H]1O)O[C@H](COP(O)(O)=O)[C@H]1O.NC1=NC=NC2=C1N=CN2[C@@H]([C@@H]1O)O[C@H](COP(O)(O)=O)[C@H]1O.P.P Chemical compound NC1=NC=NC2=C1N=CN2[C@@H]([C@@H]1O)O[C@H](COP(O)(O)=O)[C@H]1O.NC1=NC=NC2=C1N=CN2[C@@H]([C@@H]1O)O[C@H](COP(O)(O)=O)[C@H]1O.NC1=NC=NC2=C1N=CN2[C@@H]([C@@H]1O)O[C@H](COP(O)(O)=O)[C@H]1O.P.P WJXICLCJFVEKKK-PWVLCOLPSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000026214 Skeletal muscle atrophy Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-RWOPYEJCSA-N beta-D-mannose Chemical compound OC[C@H]1O[C@@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-RWOPYEJCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 108010066540 copper thionein Proteins 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical group 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000025185 skeletal muscle atrophy Effects 0.000 description 1
- 230000012232 skeletal muscle contraction Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 108010062393 zinc thionein Proteins 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides the application of oligomannuronic acid and its derivative in the medicine and health products for preparing antifatigue and anti-amyotrophia, the present invention with the ocean acidic polysaccharose with b configurations be raw material, water-soluble low-molecular mannuronic acid compound is obtained, first passage experiment of the present invention demonstrates application of the low-molecular-weight mannuronic acid in preventing and treating or improving fatigue and muscle wasting symptoms；The pharmacological action of low-molecular-weight mannuronic acid clearly, and tests prove that do not have any toxic and side effect to myocyte, is suitable to long-term taking；And low molecule mannuronic acid of the present invention derives from marine natural products, with aboundresources, is easy to industrialization, safe, the good advantage of unique structure, oral absorption, there is wide market application foreground in terms of antifatigue and muscular atrophy.
Description
Technical field
The invention belongs to marine drug field, and in particular to oligomannuronic acid and its derivative prepare it is antifatigue
With the application in anti-amyotrophic medicine and health products.
Background technology
Fatigue is the complicated physiological acoustic signals process of body, is necessarily occurred when referring to mental or physical arrival certain phase
A kind of normal physiological phenomenon.It had both indicated the temporary transient decline of the original ability to work of body, was probably again that body is developed into
The tendency of morbid state.Fatigue appearance, can cause locomitivity reduction, operating efficiency reduction, mistake and accident increase, fighting capacity
Go down.If cannot recover in time after fatigue generation, gradually accumulate, also result in " overwork ", make body that endocrine to occur disorderly
Disorderly, immunity degradation, or even there is organic disease, threaten human health.Organism fatigue can be by rest, sleep and thing
Reason method is eliminated, it can in addition contain realize antifatigue effect by extra-nutrition material and medicinal treatment.Some side chain ammonia
Base acid (BCAA) includes leucine and isoleucine etc., the catabolism in muscle, is easily oxidized to body and provides energy, to dimension
Hold the normal activity of human brain and delay and eliminate exercise induced fatigue to play an important role.In addition, also creatine, B family vitamin, dimension
Raw element C, vitamin E, vitamin A, carrotene, trace elements of selenium, copper, zinc and metallothionein etc. can also improve body
Metabolism, the generation of delay fatigue.In recent years, fatigue also increasingly enjoys the concern of people as subhealth symptom, resists tired
Labor is the generation of delay fatigue and/or the elimination of promotion fatigue, and the hot issue studied in sports medical science has been turned at present.
Amyotrophia is that skeletal muscle volume compares the description for decline state occur with the state before contemporary or itself muscle.
Amyotrophia is frequently occurred under the conditions of the related damage of aging and various malignant diseases, such as serious disease such as AIDS, cancer,
CHD etc..Amyotrophia is how relevant with the infringement of perineural motor fibre and muscle fibre primary affection, from
Clinically it is divided into neurogenic and muscle-derived two types, causes the amyotrophia of whole body diffusivity or part.Thin muscle mass changes
Change often causes the balance of albumen synthesis and degraded in muscle fibre to change.Research display：It is short-term heavy dose of or long-term super
Physiological dose will cause muscular atrophy using glucocorticoid, and it is typically characterised by protein content decline, and (mainly fast muscle is fine
Dimension), muscle fibre reduces, and muscular strength declines, fatiguability.The health care belt of the generation meeting patient of amyotrophia carrys out very big influence, in recent years
With continuing to develop for society, the amyotrophic incidence of disease also result in people in the trend for constantly rising, treatment muscular atrophy
Highest attention, current treatment method mainly has traditional Chinese and western medicine drug therapy, dietary adjustments and motion and other physical therapies, but mesh
Preceding these means reach far away preferable therapeutic effect, therefore, research and develop safe efficient, economic anti-amyotrophia medicine and
Functional food has turned into current study hotspot.
Oligomannuronic acid is a kind of intercellular polysaccharide that acquisition is separated by being extracted in marine brown, is by β-D-MANNOSE
Aldehydic acid (β-D-Mannuronic acid, M) connects the ol cpds of composition by 1,4- glycosidic bonds.At present, there is text both at home and abroad
Offering report oligomannuronic acid has the various biologicals such as anti-oxidant, anti-inflammatory, immunological regulation and anti-senile dementia activity, but
At present, on oligomannuronic acid oligosaccharides in terms of antifatigue and anti-amyotrophia research and application is there is not yet report.
The content of the invention
The medicine of antifatigue and anti-amyotrophia is being prepared it is an object of the invention to provide oligomannuronic acid and its derivative
Application in thing and health products, the present invention is experimentally confirmed oligomannuronic acid and its derivative in animal and cellular level
On there is notable protective effect to sports fatigue and muscle fiber atrophy.Compound of the invention possesses low-molecular-weight acidity oligosaccharides
Advantage, not only water-soluble strong, easily absorption, and also abundance, the mechanism of action are unique, with wide industrialization development application
Prospect.
For achieving the above object, the present invention is achieved using following technical proposals：
The application of oligomannuronic acid and its derivative in the medicine and health products for preparing antifatigue and anti-amyotrophia.
The molecular skeleton of the oligomannuronic acid and its derivative is bonded for D-MANNOSE aldehydic acid by β -1,4 glucosides
The linear oligosaccharides compound to be formed is connect, weight average molecular weight is 0.3kDa~12kDa；Wherein, oligomannuronic acid and its derivative
The general formula of molecular structure of thing is as follows：
In formula, R=H or Li, Na, K, Ca, Mg or corresponding sulphation, phosphorylation, nitrification, carboxy methylation deriveding group, n
≤60。
R '=H or corresponding sulphations, phosphorylation, nitrification, carboxy methylation deriveding group.
The consumption of the oligomannuronic acid and its derivative is 5mg/kg-100mg/kg.
The oligomannuronic acid and its derivative dramatically increase the tolerance of exercise of skeletal muscle.
The oligomannuronic acid and its derivative can reduce the accumulation of internal serum urea nitrogen after motion, reduce motion
Internal blood lactase acid accumulation afterwards.
The oligomannuronic acid and its derivative can increase hepatic glycogen and muscle glycogen content.
The oligomannuronic acid and its derivative can suppress under the protein level of skeletal muscle content that glucocorticoid causes
Drop.
Low-molecular-weight mannuronic acid is extracted from sea-tangle, bulk kelp, bladder-wrack, yellow tang, kelp or rope algae correlation brown alga
The algin for obtaining is obtained by classification and degraded.
The low-molecular-weight mannuronic acid and its derivative and anti-fatigue medicament ginseng class, wilsonii, royal jelly, three phosphorus
Adenosine monophosphate, rhodiola root, astaxanthin, spirulina, Chinese caterpillar fungus class, vitamins compounding, or with anti-amyotrophia medicine neurotrophic peptide
Class, or compound to form medicine or health products with the algin comprising oligomannuronic acid salt, brown alga oligose.
Advantages of the present invention and beneficial effect are：
1st, the present invention exhausts animal model and skeletal muscle atrophy cell model using swimming power, by the oligomeric sweet dew of experimental verification
, in the effect of antifatigue and anti-amyotrophia, research has shown that oligomannuronic acid salt can significantly prolong for uronic acid and its derivative
Swimming time long, is effectively increased the deposit of hepatic glycogen and muscle glycogen, significantly reduces serum urea and blood lactase acid after motion
Level, can strengthen mouse body endurance, bear the reinforcement of exercise load ability；Simultaneously Skeletal Muscle Cell albumen is significantly improved to contain
Amount, significantly inhibits the loss degraded of myotube protein, so as to realize the effect of antifatigue and anti-amyotrophia.Oligomeric manna sugar of the present invention
Aldehydic acid and its derivative can be used to preventing or treating fatigue and amyotrophia symptom.
2nd, oligomannuronic acid salt of the present invention derives from marine natural polysaccharide, with aboundresources, is easy to industry
Change, many advantages, such as safe and effective, there is wide development prospect in terms of antifatigue and anti-amyotrophia.
Specific embodiment
Technical scheme is described in further detail with reference to specific embodiment.
The invention provides low-molecular-weight mannuronic acid and its purposes of derivative, withered for preparing antifatigue and anti-flesh
The medicine and health products of contracting.The present invention proves that low-molecular-weight mannuronic acid and its derivative can effectively prolong by experiment first
The swimming time of Exhausted mice long, significantly reduces the level of blood lactase acid and serum urea nitrogen, and significantly improves the liver of Exhausted mice
The content of glycogen and muscle glycogen；Simultaneously low-molecular-weight mannuronic acid can significantly inhibit myotube protein that glucocorticoid causes with
And the reduction of α-actin contents, and effectively suppress the degradation process of myotube protein；Therefore can be used to prevent, treat or improve
Fatigue and muscle wasting symptoms.
Low-molecular-weight mannuronic acid in the present invention can be from sea-tangle, bulk kelp, bladder-wrack, yellow tang, kelp or rope algae
Extract the algin for obtaining in related brown alga to be obtained by classification and degraded, it is also possible to by being chemically synthesized and obtaining.It is described
Oligomannuronic acid salt is lithium salts, sodium salt, sylvite, calcium salt or the magnesium salts of the oligomannuronic acid of different molecular weight, described
The molecular skeleton of oligomannuronic acid and its derivative connects what is formed for D-MANNOSE aldehydic acid (M) by β -1,4 glycosidic bonds
Linear oligosaccharides compound, constitutes between saccharide residue by β-Isosorbide-5-Nitrae-D-MANNOSE aldehydic acid, and structural formula is as follows：
Its weight average molecular weight range is 0.3kD~15kD (preferably 1kD~10kD), n≤60 (preferably 1~30), formula
In, R=H or Li, Na, K, Ca, Mg or corresponding sulphation, phosphorylation, nitrification, carboxy methylation deriveding group, R '=H or corresponding
Sulphation, phosphorylation, nitrification, carboxy methylation deriveding group.
Animal pattern and glucocorticoid inducible amyotrophy model cell are exhausted according to classical tired power, be have rated oligomeric
The influence of mannuronic acid and its derivative to fatigue and muscle wasting symptoms.
Embodiment 1：Protective effect of the oligomannuronic acid salt (LM) to disposable swimming Exhausted mice
1) influences of the LM to Exhausted mice swimming time
Model is exhausted i.e. using mouse swimming power:After mouse continuous gavage 2 weeks, positive drug selects n-octacosanol (10mg/
Kg), oligomannuronic acid salt is divided into low dose group (25mg/kg), middle dose group (50mg/kg), high dose group (100mg/
), kg in after last time treatment half an hour, the galvanized wire of 3% body weight that mouse tail is born a heavy burden, (unit is to be placed in 50 × 50 × 40
Cm swimming pool went swimming), 30 ± 1 DEG C of water temperature, record mouse starts swimming, and to trip, power does not exhaust and sinks to underwater and can not float for 8 seconds
Time untill going out the water surface, i.e. mouse swimming power exhaust the time.
Result is as shown in table 1：Determining mouse persistent movement can reflect the endurance of body to the time that power exhausts.By the institute of table 1
Show, swimming time has dose-effect relationship with LM, high dose group increases most relative to blank group swimming time,
90.5%, median dose group increases by 66.2%, and n-octacosanol group increased 67.5%, show LM high doses group and middle dose group
The exercise tolerance of mouse can be improved, with antifatigue effect.
Influences of the LM of table 1 to the mice burden swimming time
**p<0.01, compare with model group.
2) influences of the LM to Exhausted mice blood lactase acid (BLA) and serum urea nitrogen (BUN)
Model is exhausted i.e. using mouse swimming power:After mouse continuous gavage 2 weeks, positive drug selects n-octacosanol (10mg/
Kg), oligomannuronic acid salt is divided into low dose group (25mg/kg), middle dose group (50mg/kg), high dose group (100mg/
), kg in after last time treatment half an hour, tail vein takes blood, determines the preceding blood urea nitrogen (BUN) of swimming, blood lactase acid (BLA) and contains
Amount, the galvanized wire of 3% body weight that mouse tail is born a heavy burden is placed in 50 × 50 × 40 swimming pool went swimming, 30 ± 1 DEG C of water temperature, swimming 1
Taken out after hour, removal is born a heavy burden, eyeball takes blood after quiet 15min, determine mouse blood urea nitrogen (BUN), blood lactase acid (BLA) and contain
Amount.Generally cause the biochemical indicator of fatigue by determining, the appearance and evolution of fatigue can be observed.When mouse body is long
Between when can not obtain enough energy by sugar, catabolism of fat, protein and amino acids catabolism will be strengthened, and
And the metabolism of nucleotides is also accelerated therewith, the final product of this metabolic pathway all generates urea.Plasma wrea produces fewer, says
Bright mouse body endurance is stronger, can more bear exercise load.
From table 2, each group serum urea nitrogen difference is not obvious before swimming, and each group serum urea nitrogen content is obvious after swimming
Increase.After swimming, compared with model group, LM middle dosages and high dose group and n-octacosanol group serum urea nitrogen are substantially less than
Model group, this says that LM can reduce the accumulation of serum urea nitrogen in exercised rats body.
Blood lactase acid is the product of glycolysis under anoxic conditions, and with the quickening of glycolysis speed, lactic acid contains in muscle
Amount constantly accumulation, causes Cellular pH value to decline, and produces a series of Biochemical changes, and then cause fatigue.Accumulated in muscle more
Lactic acid, the performance degree of fatigue is more serious.It thus is seen that each group Serum lactic acid content difference is not obvious before swimming, it is each after swimming
Group Serum lactic acid content substantially increases.And model group Serum lactic acid content is said apparently higher than high dose group in LM and n-octacosanol group
Bright LM can reduce blood lactase acid accumulation in vivo after mouse movement, accelerate the recovery of body.
Influence of the table 2 to mice serum urea nitrogen (BUN) and blood lactase acid (BLA)
*p<0.05, compare with model group
3) influences of the LM to Exhausted mice hepatic glycogen and Body development
Model is exhausted i.e. using mouse swimming power:After mouse continuous gavage 2 weeks, positive drug selects n-octacosanol (10mg/
Kg), oligomannuronic acid salt is divided into low dose group (25mg/kg), middle dose group (50mg/kg), high dose group (100mg/
), kg in after last time treatment half an hour, the galvanized wire of 3% body weight that mouse tail is born a heavy burden is placed in 50 × 50 × 40 swimming pool
Went swimming, 30 ± 1 DEG C of water temperature, swimming is taken out after 1 hour, and removal is born a heavy burden, and after eyeball takes blood, dislocation immediately is put to death, and takes out liver
And hind leg muscle, hepatic glycogen (LG) and muscle glycogen (MG) content is determined respectively.Due to the deposit of glycogen in living organism and motion
Endurance is proportionate.When run duration increases, muscle glycogen can be largely consumed, make the reduction of living organism locomitivity, fatigue occur,
The intake for blood sugar is increased simultaneously, when decomposition rate of the intake speed more than hepatic glycogen, blood sugar level reduction.Because
To central nervous system, blood sugar reduction can cause central nervous system to be short of power, so as to cause whole body fatigue for blood sugar energy supply.
Experimental result (table 3) shows, the hepatic glycogen and muscle glycogen of middle and high dosage group and n-octacosanol group are apparently higher than sky
White group, illustrating the LM of middle and high dosage group can increase hepatic glycogen and muscle glycogen content, and glycogen can directly resolve into glucose
Into blood, utilized for its hetero-organization by blood circulation.Therefore, the LM of middle and high dosage group can delay and resist fatigue
Occur.
Influences of the table 3LM to mouse hepatic glycogen (LG) and muscle glycogen (MG)
*p<0.05,**p<0.01 compares with model group；#p<0.05, compare with positive drug.
Embodiment 2：Oligomannuronic acid salt (LM) protection myocyte avoids the effect of myotube atrophy
1) influences of the LM to C2C12 myotube protein contents
This experiment forms C2C12 myotubes in 8 days using mice skeletal C2C12 myoblast differentiations, uses dexamethasone DEX
(100nM) stimulates 24 hours, sets up classical amyotrophia cell model.α-actin are one kind of actin subclass, are myogens
The abundant albumen of fiber content, its content influences the contractility of skeletal muscle.Researcher often with the change of the albumen of α-actin come
Reflect the change of Skeletal Muscle Contraction albumen.There is decline of the phase with α-actin protein contents in muscular atrophy.
Influences of the LM to protein level of skeletal muscle content is observed in experiment.Muscle total protein is detected using BCA methods, is used
The content of western Blot methods detection α-actin, as a result as shown in table 4, dexamethasone DEX (100nM) treatment myotubes
24 hours afterwards, and total protein content is consistent with α-actin content downward trends, is respectively provided with significant difference, shows that model is set up
Success.The LM of test dose can significantly increase total protein content and α-actin contents, and in dose-dependent effect.This table
Bright LM can effectively suppress the amyotrophia phenomenon of the protein level of skeletal muscle content decline that glucocorticoid causes.
Influences of the LM of table 4 to Skeletal Muscle Cell total protein content and α-actin contents
##p<0.01, compare with blank group；*p<0.05,**p<0.01 compares with model group.
2) influence that LM degrades to C2C12 myotube proteins
This experiment forms C2C12 myotubes in 8 days using mice skeletal C2C12 myoblast differentiations, uses dexamethasone DEX
(100nM) stimulates 24 hours, sets up classical amyotrophia cell model.Proteins ubiquitin degradation pathway is the master that skeletal muscle is lost
Want reason.
Influences of the LM to myotube protein ubiquitination Degradation Level is observed by western Blot methods in experiment.As a result table 5
Shown, the ubiquitination level of albumen significantly rises dexamethasone DEX (100nM) treatment myotubes, shows mould afterwards within 24 hours
The PD of type cell accelerates.The LM of test dose can significantly suppress albumen ubiquitination degraded, and in dosage according to
Rely effect.This shows that LM can effectively suppress the loss of the protein level of skeletal muscle that glucocorticoid causes, and dosage is in 100ug/ml
When, inhibiting rate is up to 35.7%, is acted on preferable anti-amyotrophia.
Influences of the LM of table 5 to Skeletal Muscle Cell proteins ubiquitin degradation pathway
##p<0.01, compare with blank group；*p<0.05,**p<0.01 compares with model group.
It is of the invention test result indicate that, low-molecular-weight mannuronic acid salt can preferably increase the exercise tolerance of skeletal muscle
Power, accelerates the recovery of tired body, hence it is evident that suppresses myotube protein and loses the effect for decomposing and reaching antifatigue and anti-amyotrophia.Should
Low-molecular-weight mannuronic acid salt can be used for the prevention of fatigue and amyotrophia illness as a kind of natural health-care products or medicine
And treatment.The product is originated Yu Haiyang marine alga, with aboundresources, it is easy to industrialization, and safety it is high the advantages of, antifatigue and
Anti- amyotrophia aspect has wide market and application prospect.The present invention will offer reference meaning for the higher value application of ocean marine alga
Justice and enlightenment.
The above embodiments are merely illustrative of the technical solutions of the present invention, rather than is limited；Although with reference to foregoing reality
Example is applied to be described in detail the present invention, for the person of ordinary skill of the art, still can be to foregoing implementation
Technical scheme described in example is modified, or carries out equivalent to which part technical characteristic；And these are changed or replace
Change, do not make the spirit and scope of the essence disengaging claimed technical solution of the invention of appropriate technical solution.
Claims (9)
1. application of the oligomannuronic acid in the medicine and health products for preparing antifatigue and anti-amyotrophia, it is characterised in that：
The molecular skeleton of the oligomannuronic acid connects the linear oligosaccharides to be formed for D-MANNOSE aldehydic acid by β -1,4 glycosidic bonds
Compound, weight average molecular weight is 0.3 kDa~12 kDa；Wherein, the general formula of molecular structure of oligomannuronic acid is as follows：
In formula, R=H or Li, Na, K, Ca, Mg or corresponding sulphation, phosphorylation, nitrification, carboxy methylation deriveding group, n≤
60；
R '=H or corresponding sulphations, phosphorylation, nitrification, carboxy methylation deriveding group.
2. oligomannuronic acid according to claim 1 is in the medicine and health products for preparing antifatigue and anti-amyotrophia
Application, it is characterised in that：The consumption of the oligomannuronic acid is 5 mg/kg-100 mg/kg.
3. oligomannuronic acid according to claim 1 is in the medicine and health products for preparing antifatigue and anti-amyotrophia
Application, it is characterised in that：The oligomannuronic acid dramatically increases the tolerance of exercise of skeletal muscle.
4. oligomannuronic acid according to claim 1 is in the medicine and health products for preparing antifatigue and anti-amyotrophia
Application, it is characterised in that：The oligomannuronic acid can reduce the accumulation of internal serum urea nitrogen after motion, reduce motion
Internal blood lactase acid accumulation afterwards.
5. oligomannuronic acid according to claim 1 is in the medicine and health products for preparing antifatigue and anti-amyotrophia
Application, it is characterised in that：The oligomannuronic acid can increase hepatic glycogen and muscle glycogen content.
6. oligomannuronic acid according to claim 1 is in the medicine and health products for preparing antifatigue and anti-amyotrophia
Application, it is characterised in that：The oligomannuronic acid can suppress under the protein level of skeletal muscle content that glucocorticoid causes
Drop.
7. oligomannuronic acid according to claim 1 is in the medicine and health products for preparing antifatigue and anti-amyotrophia
Application, it is characterised in that：The n is 1~30.
8. oligomannuronic acid according to claim 1 is in the medicine and health products for preparing antifatigue and anti-amyotrophia
Application, it is characterised in that：Oligomannuronic acid is extracted from sea-tangle, bulk kelp, bladder-wrack, yellow tang, kelp or rope algae
The algin for arriving is obtained by classification and degraded.
9. oligomannuronic acid according to claim 1 is in the medicine and health products for preparing antifatigue and anti-amyotrophia
Application, it is characterised in that：The oligomannuronic acid and anti-fatigue medicament ginseng class, wilsonii, royal jelly, Adenosine triphosphate
Glycosides, rhodiola root, astaxanthin, spirulina, Chinese caterpillar fungus class, vitamins compounding, or with anti-amyotrophia medicine neurotrophy peptides, or
Person compounds to form medicine or health products with the algin comprising oligomannuronic acid salt, algin oligosaccharide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510018297.9A CN104666327B (en) | 2015-01-14 | 2015-01-14 | The application of oligomannuronic acid and its derivative in the medicine and health products for preparing antifatigue and anti-amyotrophia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510018297.9A CN104666327B (en) | 2015-01-14 | 2015-01-14 | The application of oligomannuronic acid and its derivative in the medicine and health products for preparing antifatigue and anti-amyotrophia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104666327A CN104666327A (en) | 2015-06-03 |
| CN104666327B true CN104666327B (en) | 2017-07-07 |
Family
ID=53302265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510018297.9A Expired - Fee Related CN104666327B (en) | 2015-01-14 | 2015-01-14 | The application of oligomannuronic acid and its derivative in the medicine and health products for preparing antifatigue and anti-amyotrophia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104666327B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108308493A (en) * | 2018-01-25 | 2018-07-24 | 江苏神华药业有限公司 | A kind of anti-fatigue solid beverage and preparation method of astaxanthin-containing |
| CN110882264B (en) * | 2019-11-13 | 2021-03-26 | 青岛海洋生物医药研究院股份有限公司 | Pharmaceutical composition of gastrodin and mannuronic acid oligosaccharide and application thereof |
| CN115005447B (en) * | 2022-06-16 | 2024-02-06 | 青岛海关技术中心 | Application of oligoguluronic acid in preparation of anti-fatigue product |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003099870A2 (en) * | 2002-05-29 | 2003-12-04 | Centre D'etude Et De Valorisation Des Algues Sa | Methods for obtaining oligomannuronates et guluronates, products obtained and use thereof |
| CN103446174A (en) * | 2013-09-12 | 2013-12-18 | 中国海洋大学 | Application of mannuronic acid oligomers in preparing medicines, health products or dietary supplements for preventing and treating alcoholic liver injury |
| CN103961365A (en) * | 2014-03-25 | 2014-08-06 | 青岛海洋生物医药研究院股份有限公司 | Application of mannan-oligosaccharide aldehyde acid salt in preparing medicine for preventing and curing liver damage, various hepatitis, liver fibrosis or cirrhosis |
-
2015
- 2015-01-14 CN CN201510018297.9A patent/CN104666327B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003099870A2 (en) * | 2002-05-29 | 2003-12-04 | Centre D'etude Et De Valorisation Des Algues Sa | Methods for obtaining oligomannuronates et guluronates, products obtained and use thereof |
| CN103446174A (en) * | 2013-09-12 | 2013-12-18 | 中国海洋大学 | Application of mannuronic acid oligomers in preparing medicines, health products or dietary supplements for preventing and treating alcoholic liver injury |
| CN103961365A (en) * | 2014-03-25 | 2014-08-06 | 青岛海洋生物医药研究院股份有限公司 | Application of mannan-oligosaccharide aldehyde acid salt in preparing medicine for preventing and curing liver damage, various hepatitis, liver fibrosis or cirrhosis |
Non-Patent Citations (1)
| Title |
|---|
| 海带多糖药理作用的研究进展;邓长江邓;《食品与药品》;20061231;第8卷(第4A期);第30-32页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104666327A (en) | 2015-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Geng et al. | Antifatigue functions and mechanisms of edible and medicinal mushrooms | |
| Hu et al. | Fucosylated chondroitin sulfate from sea cucumber improves glucose metabolism and activates insulin signaling in the liver of insulin-resistant mice | |
| AU2019203595B2 (en) | Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) for decreasing fat mass | |
| CN103446174B (en) | Oligomannuronic acid is preparing the application in the medicine of prevention and therapy alcoholic liver injury, health product or dietary supplement | |
| CN104666327B (en) | The application of oligomannuronic acid and its derivative in the medicine and health products for preparing antifatigue and anti-amyotrophia | |
| Hu et al. | Fucosylated chondroitin sulfate from sea cucumber in combination with rosiglitazone improved glucose metabolism in the liver of the insulin-resistant mice | |
| KR102195547B1 (en) | Use of Cistanke Tubulosa Extract and Isoacteoside in Muscle Protection | |
| CN111568945A (en) | Compound cyclocarya paliurus preparation | |
| US20140221472A1 (en) | Use of myricetin or derivatives thereof as a cathepsin k inhibitor | |
| CN103446165A (en) | Application of guluronic acid oligomers in preparing medicines, health products or dietary supplements for preventing and treating alcoholic liver injury | |
| CN105395563A (en) | Application of oligoguluronic acid and derivative thereof in preparation of drugs and health products used for preventing and treating hyperlipidemia and complications thereof | |
| Choi et al. | Effect of Dongchunghacho (Cordyceps militaris) on hyperglycemia and dyslipidemia in type 2 diabetic db/db mice | |
| CN104857180B (en) | Composition for resisting fatigue and improving immunity and preparation method and application thereof | |
| CN115005447B (en) | Application of oligoguluronic acid in preparation of anti-fatigue product | |
| CN101032562A (en) | Health care product having functions of conditioning blood pressure and protecting haemal system of heart and brain | |
| OUDAH et al. | The effect of green tea extract and metformin on diabetic mellitus induce in male rats | |
| JP4879520B2 (en) | Liver fibrosis inhibitor | |
| CN114191499B (en) | Traditional Chinese medicine composition for relieving liver and kidney injury | |
| JP2014187997A (en) | Anti-aging food | |
| CN112471514B (en) | Food composition for promoting physical energy recovery after exercise | |
| CN103860578A (en) | Use of lentinan as antidepressant drug | |
| KR101297034B1 (en) | Composition for preventing and treating metabolic syndrome comprising eel extract | |
| CN100551357C (en) | The application of prepared from coriolus versicolor mycelium in preparation resisting fatigue medicament | |
| WO2017121328A1 (en) | Methods and compositions for reducing body weight and increasing gut motility | |
| CN117599091A (en) | Application of bezoar in preparing medicine for preventing or treating hyperuricemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170707 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |